This article is a correction to:
Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity
Wilbert Bouwman
Wim Verhaegh
Anja van de Stolpeby Bouwman W, Verhaegh W and van de Stolpe A (2022). Front. Pharmacol. 13:1008976. doi: 10.3389/fphar.2022.1008976
In the published article, there was an error in Figure 2 as published. In this figure for the prediction and assessment of response to anti-TNFα remission-induction treatment in CD (A) a different TGFbeta pathway model version was used. The corrected Figure 2 and its caption appear below.
FIGURE 2
FIGURE 2. Prediction and assessment of response to anti-TNFα remission-induction treatment in CD (A) and UC (B). Datasets GSE16879. STP activity analysis of intestinal mucosa samples for prediction of response to anti-TNFα remission induction treatment in patients with CD and UC. STP PAS before and after remission induction treatment. For details, see Methods. STP PAS are shown for the AR, MAPK, NFκB, TGFβ, JAK-STAT1/2, JAK-STAT3, and Wnt STPs. Two sided Mann–Whitney–Wilcoxon statistical tests were performed; p-values are indicated in the figures as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: not significant. For supporting analysis results, see Supplementary Table S1.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: ulcerative colitis, crohn’s disease, IBD, signal transduction pathway, treatment response
Citation: Bouwman W, Verhaegh W and van de Stolpe A (2023) Corrigendum: Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity. Front. Pharmacol. 14:1183639. doi: 10.3389/fphar.2023.1183639
Received: 10 March 2023; Accepted: 28 March 2023;
Published: 05 April 2023.
Edited and reviewed by:
Paola Patrignani, University of Studies G. d’Annunzio Chieti and Pescara, ItalyCopyright © 2023 Bouwman, Verhaegh and van de Stolpe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wilbert Bouwman, Wilbert.bouwman@philips.com